Alexandria Real Estate Equities Class Action Notice, Deadline January 26
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Should l Buy ARE?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Alexandria Real Estate Equities securities between January 27 and October 27, 2025, that the lead plaintiff deadline is January 26, and failing to apply on time may result in lost claims.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which reduces financial barriers and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that defendants misled investors by providing overly positive information regarding Alexandria's expected revenue and funds from operations while concealing adverse facts about its Long Island City property, resulting in investor losses.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and significant impact in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARE
Wall Street analysts forecast ARE stock price to rise
15 Analyst Rating
3 Buy
12 Hold
0 Sell
Hold
Current: 55.120
Low
41.00
Averages
56.85
High
67.00
Current: 55.120
Low
41.00
Averages
56.85
High
67.00
About ARE
Alexandria Real Estate Equities, Inc. is a life science real estate investment trust. The Company is an owner, operator and developer of collaborative life science, agricultural technology (agtech), and advanced technology mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. The Company, through its venture capital platform, provides strategic capital to life science, agrifoodtech, climate innovation, and technology companies. Its tenants include multinational pharmaceutical companies; public and private biotechnology companies; life science product, service and medical device companies; digital health, technology, and agtech companies; academic and medical research institutions; United States government research agencies; non-profit organizations, and venture capital firms. It has a Labspace asset base predominantly concentrated in markets with barriers to entry.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Complete Liquidation: Socorro Asset Management LP fully liquidated its stake in Alexandria Real Estate Equities during Q4 2025 by selling 62,346 shares, resulting in a $5.20 million decrease in position value, indicating a lack of confidence in the company.
- Declining Asset Management Proportion: Prior to liquidation, Alexandria represented 1.9% of Socorro's assets under management, and post-liquidation, Socorro holds no ARE shares, reflecting a strategic shift in its investment approach towards the REIT.
- Poor Financial Performance: Alexandria reported a net loss of $1.4 billion in 2026, despite funds from operations at $1.5 billion, which was a 5.8% decline from 2024, highlighting underperformance in its biopharmaceutical-focused real estate portfolio.
- Significant Dividend Cut: Alexandria reduced its quarterly dividend by 45% to $0.72 per share in December, resulting in a current yield of 5.3%, which may negatively impact investor confidence and future capital inflows.
See More
- Liquidation Transaction: According to a SEC filing dated February 17, 2026, Socorro Asset Management fully liquidated its stake in Alexandria Real Estate Equities by selling 62,346 shares, reducing its position from 1.9% to zero, indicating a cautious outlook on the company's future prospects.
- Performance Decline: As of February 18, 2026, ARE shares were priced at $54.16, down 39.8% over the past year, underperforming the S&P 500 by 52.1 percentage points, reflecting market disappointment with its biopharmaceutical-focused portfolio.
- Financial Condition: ARE reported a net loss of $1.4 billion in 2026, with funds from operations at $1.5 billion, which is 5.8% lower than in 2024, indicating a deterioration in financial health that may affect future investment attractiveness.
- Dividend Adjustment: In December 2026, ARE reduced its quarterly dividend by 45% to $0.72 per share, resulting in a current yield of 5.3%, which may undermine investor confidence seeking stable income.
See More
- Complete Liquidation: Socorro Asset Management LP disclosed in an SEC filing dated February 17, 2026, that it fully liquidated its stake in Alexandria Real Estate Equities by selling 62,346 shares, reducing its position from 1.9% to zero, indicating a pessimistic outlook on the company's future prospects.
- Performance Decline: As of February 18, 2026, Alexandria Real Estate's shares were priced at $54.16, down 39.8% over the past year and underperforming the S&P 500 by 52.1 percentage points, reflecting market concerns regarding its biopharmaceutical-focused assets.
- Financial Strain: The company reported a net loss of $1.4 billion in 2026, despite funds from operations reaching $1.5 billion, which was a 5.8% decline from 2024, indicating ongoing pressure on profitability that may affect future investment appeal.
- Dividend Cut: Alexandria Real Estate reduced its quarterly dividend by 45% to $0.72 per share in December, resulting in a current yield of 5.3%, which may undermine investor confidence in its dividend sustainability and further impact stock performance.
See More
- Strong Earnings Report: Despite a 13% decline in both revenue and funds from operations (FFO) in Q4, these figures exceeded Wall Street expectations, leading to a 16% increase in share price, indicating market confidence in the company's future.
- Stock Price Volatility: IIP's shares have fallen 73% over the past five years, meaning the Q4 performance did not face high expectations, providing investors with a relatively low entry point.
- High Dividend Yield: With a staggering 13.9% dividend yield, the company needs FFO to rebound to maintain this level, and Chairman Alan Gold remains optimistic, citing strong leasing activity as a driver for revenue growth.
- Strategic Investment: IIP has funded $150 million of its $270 million commitment to IQHQ, expecting a 13.5% yield, showcasing the company's diversification strategy into life sciences, leveraging Alan Gold's experience for future success.
See More

- Revenue and FFO Decline: Despite a 13% drop in both revenue and funds from operations (FFO) in Q4, the company exceeded Wall Street expectations, demonstrating resilience in adversity, which positively impacted the stock price, rising 16%.
- Litigation Proceeds: The company benefited from resolving several litigation cases, mitigating the impact of revenue and FFO declines due to defaults, and is expected to continue improving financial performance, boosting investor confidence.
- Strategic Investment in Life Sciences: IIP has funded $150 million of its $270 million commitment to IQHQ, reflecting its diversification strategy into the life sciences sector, which is anticipated to provide new growth momentum in the future.
- High Dividend Yield: Despite challenges, IIP maintains a staggering 13.9% dividend yield, with management optimistic about sustaining this level, emphasizing that strong leasing activity will drive future revenue growth.
See More
- Earnings Release Schedule: Alexandria Real Estate will release its Q1 2026 operating and financial results after market close on April 27, 2026, providing investors with crucial financial data and operational performance insights.
- Conference Call Timing: The company has scheduled a conference call for April 28, 2026, at 2:00 p.m. ET to discuss the financial results and answer investor questions, enhancing communication with shareholders.
- Participation Details: Investors can join the call by dialing (833) 366-1125 (U.S./Canada) or (412) 902-6738 (international), ensuring they receive timely updates on the company's latest developments.
- Replay Information: A replay of the conference call will be available from April 28, 2026, at 4:00 p.m. until May 5, 2026, at 4:00 p.m., with access via (855) 669-9658 (U.S./Canada) or (412) 317-0088 (international), ensuring no important information is missed.
See More









